Challenges in Predictive Chemosensitivity Testing
Author Information
Author(s): P.R. Twentyman
Primary Institution: MRC Clinical Oncology and Radiotherapeutics Unit, Cambridge
Hypothesis
Can a reliable system for predictive chemosensitivity testing be developed for clinical use?
Conclusion
Current predictive chemosensitivity tests are not yet reliable enough for common solid tumors.
Supporting Evidence
- Current predictive tests have a true prediction rate of sensitivity between 65-75%.
- True prediction of resistance is often around 90%, but this depends on the actual response rate in vivo.
- Clonogenic assays require a single cell suspension, which is difficult to achieve.
- Non-clonogenic assays may provide better predictions of short to medium term clinical response.
Takeaway
Doctors want to know which cancer drugs will work best for patients, but it's really hard to test this accurately with current methods.
Methodology
The article discusses various methods of chemosensitivity testing, including clonogenic assays and short-term biochemical assays.
Potential Biases
There is a risk of bias due to the reliance on small samples and the difficulty in mimicking in vivo conditions.
Limitations
The tests may not accurately represent the complexity of tumor responses and are affected by tumor heterogeneity.
Want to read the original?
Access the complete publication on the publisher's website